← Sarepta Therapeutics, Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | ($267.3m) | ($50.7m) | ($361.9m) | ($715.1m) | ($554.1m) | ($418.8m) | ($703.5m) | ($536.0m) | $235.2m | ($713.4m) | — | |
| Depreciation, Depletion and Amortization | $5.6m | $8.1m | $12.2m | $30.5m | $26.9m | $38.0m | $41.9m | $44.4m | $37.7m | $44.5m | $44.7m | |
| Depreciation | $5.0m | $6.4m | $10.2m | $22.8m | $25.2m | $36.6m | $40.0m | $42.5m | $42.7m | $51.4m | $44.7m | |
| Amortization of Debt Issuance Costs | — | ($15.2m) | — | ($689k) | ($39k) | $0 | $7.5m | $5.2m | $5.0m | $12.1m | — | |
| Amortization of Intangible Assets | — | $1.1m | $865k | $849k | $662k | $706k | $714k | $1.6m | $2.4m | $2.6m | — | |
| Deferred Income Tax Expense (Benefit) | — | — | ($240k) | ($376k) | ($245k) | ($309k) | ($612k) | ($165k) | ($249k) | ($363k) | — | |
| Share-based Payment Arrangement, Noncash Expense | $30.0m | $30.5m | $50.1m | $78.6m | $108.1m | $113.9m | $233.0m | $182.5m | $184.3m | $123.4m | $98.8m | |
| Share-based Payment Arrangement, Expense | $30.0m | $30.5m | $50.1m | $78.6m | $108.1m | $113.9m | $233.0m | $182.5m | — | $14k | $98.8m | |
| Equity Method Investment, Other than Temporary Impairment | — | — | — | — | — | $4.5m | $2.6m | $30.3m | $0 | $0 | — | |
| Income (Loss) from Equity Method Investments | — | — | — | — | — | — | — | — | $0 | $0 | — | |
| Nonoperating Income (Expense) | ($535k) | $123.0m | ($19.0m) | ($8.3m) | $11.1m | $40.8m | ($153.8m) | ($252.3m) | $42.7m | ($2.4m) | — | |
| Other Nonoperating Income (Expense) | ($535k) | ($2.0m) | ($656k) | ($236k) | $517k | ($936k) | — | $33.1m | $42.7m | ($19.3m) | — | |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts Receivable | $1.3m | $24.2m | $19.6m | $41.8m | $10.5m | $51.6m | $61.6m | $185.7m | $201.7m | ($203.8m) | $150.5m | |
| Increase (Decrease) in Inventories | $12.8m | $70.8m | $41.8m | $45.9m | $60.6m | $83.8m | $50.8m | $147.7m | $395.2m | $301.1m | ($94.4m) | |
| Inventory Write-down | — | — | — | — | — | — | — | — | — | $165.3m | — | |
| Gain (Loss) on Disposition of Other Assets | — | — | — | — | — | — | ($10.8m) | — | — | — | — | |
| Net Cash Provided by (Used in) Operating Activities | ($245.8m) |
($232.0m)
+5.62%
|
($388.7m)
-67.53%
|
($456.5m)
-17.45%
|
$107.5m
+123.54%
|
($443.2m)
-512.38%
|
($325.3m)
+26.59%
|
($501.0m)
-53.99%
|
($205.8m)
+58.92%
|
($205.5m)
+0.15%
|
$111.0m
+154.02%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | $5.3m | $12.0m | $61.2m | $59.6m | $82.2m | $38.5m | $30.8m | $76.1m | $137.0m | $102.0m | ($36.0m) | |
| Cash, Cash Equivalents, and Short-term Investments | $329.3m | $1.1b | $1.2b | $1.1b | $1.9b | $2.1b | $2.0b | $1.7b | — | — | — | |
| Gain (Loss) on Investments | — | — | — | — | — | — | — | — | — | ($15.9m) | $52.8m | |
| Payments to Acquire Businesses, Net of Cash Acquired | — | — | — | $172.6m | — | — | — | — | — | — | — | |
| Net Cash Provided by (Used in) Investing Activities | ($90.2m) | ($178.8m) | ($370.5m) | $286.7m | ($121.7m) | $495.4m | ($1.0b) | ($165.8m) | $755.6m | $69.6m | $100.8m | |
| Cash flows from financing activities: | ||||||||||||
| Gain (Loss) on Extinguishment of Debt | — | — | ($2.3m) | — | $0 | $0 | ($125.4m) | ($387.3m) | $0 | $16.9m | — | |
| Proceeds from Issuance of Long-term Debt | — | $30.0m | — | — | $291.1m | — | $0 | — | — | — | $0 | |
| Payments for Repurchase of Common Stock | — | — | — | — | — | — | — | — | — | $25.0m | — | |
| Proceeds from Issuance of Common Stock | $364.8m | $354.0m | $513.4m | $365.4m | $312.1m | $0 | $0 | $0 | $0 | $20.0m | $20.0m | |
| Net Cash Provided by (Used in) Financing Activities | $378.1m |
$888.1m
+134.86%
|
$530.1m
-40.30%
|
$642.6m
+21.20%
|
$682.3m
+6.19%
|
$561.6m
-17.70%
|
$232.5m
-58.60%
|
$125.0m
-46.24%
|
$124.8m
-0.16%
|
($168.3m)
-234.88%
|
($156.8m)
+6.88%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $42.1m | — | ($229.0m) | $472.8m | $668.1m | $613.8m | ($1.1b) | ($541.8m) | $674.6m | ($304.2m) | $581.3m | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $122.6m | $599.8m | $370.8m | $843.6m | $1.5b | $2.1b | $985.8m | $444.0m | $1.1b | $814.4m | $581.3m | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Proceeds from Stock Options Exercised | — | $15.2m | $50.2m | $36.6m | $84.0m | $20.8m | $30.0m | $51.2m | $79.5m | $18.7m | — | |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | $1.6m | $1.9m | $11.3m | $8.6m | $34.4m | $55.9m | $44.4m | $15.9m | $15.9m | $14.9m | — | |
| Income Taxes Paid, Net | — | $5.3m | $1.5m | $933k | $2.5m | $583k | $1.7m | $15.1m | $22.6m | $37.6m | — | |
| Additional Financial Items | ||||||||||||
| Gain (Loss) on Disposition of Assets | ($293k) | ($805k) | ($3.9m) | — | — | — | — | — | — | — | — | |
| Gain (Loss) on Disposition of Intangible Assets | — | $125.0m | — | — | $108.1m | $102.0m | $0 | $102.0m | $0 | $0 | — | |
| Income Tax Expense (Benefit) | — | $2.1m | ($692k) | $1.2m | $1.1m | ($168k) | $13.5m | $15.9m | $25.5m | $11.2m | — | |
| Investment Income, Interest | — | $1.8m | $6.8m | $7.2m | $3.0m | $354k | $16.5m | $36.3m | $30.6m | $30.8m | — | |
| Restructuring Costs | $4.6m | $3.0m | ($2.2m) | — | — | — | — | — | — | $134k | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.